相似文献
1
Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance.
Br J Cancer. 2000 Jan;82(2):488-91. doi: 10.1054/bjoc.1999.0947.
2
Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
Cancer Res. 1997 Nov 15;57(22):5086-92.
3
4
Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
Cancer Res. 2000 Oct 15;60(20):5747-53.
5
Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Cancer Chemother Pharmacol. 2004 Feb;53(2):155-62. doi: 10.1007/s00280-003-0701-1. Epub 2003 Sep 23.
6
7
8
Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells.
J Cancer Res Clin Oncol. 2002 Jul;128(7):349-57. doi: 10.1007/s00432-002-0349-y. Epub 2002 Jun 26.
9
Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.
Cancer Res. 1998 Dec 1;58(23):5298-300.
10
Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
Br J Cancer. 2001 Sep 1;85(5):747-51. doi: 10.1054/bjoc.2001.1966.
引用本文的文献
1
Chemosensitivity to doxorubicin in primary cells derived from tumor of FVB/N-Trp53 with TALEN-mediated Trp53 mutant gene.
Lab Anim Res. 2023 Oct 20;39(1):23. doi: 10.1186/s42826-023-00175-2.
2
GSDME Increases Chemotherapeutic Drug Sensitivity by Inducing Pyroptosis in Retinoblastoma Cells.
Oxid Med Cell Longev. 2022 Mar 29;2022:2371807. doi: 10.1155/2022/2371807. eCollection 2022.
3
Novel Long Noncoding RNA 005620 Induces Epirubicin Resistance in Triple-Negative Breast Cancer by Regulating ITGB1 Expression.
Front Oncol. 2021 Mar 4;11:592215. doi: 10.3389/fonc.2021.592215. eCollection 2021.
4
Chemotherapy Resistance Mechanisms in Advanced Skin Cancer.
Oncol Rev. 2017 Mar 24;11(1):326. doi: 10.4081/oncol.2017.326. eCollection 2017 Mar 3.
5
Modulation of topoisomerase IIα expression and chemosensitivity through targeted inhibition of NF-Y:DNA binding by a diamino p-anisyl-benzimidazole (Hx) polyamide.
Biochim Biophys Acta Gene Regul Mech. 2017 May;1860(5):617-629. doi: 10.1016/j.bbagrm.2016.10.005. Epub 2016 Oct 24.
6
RAD001 can reverse drug resistance of SGC7901/DDP cells.
Tumour Biol. 2014 Sep;35(9):9171-7. doi: 10.1007/s13277-014-1719-1. Epub 2014 Jun 12.
7
Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance.
PLoS One. 2012;7(2):e30804. doi: 10.1371/journal.pone.0030804. Epub 2012 Feb 2.
8
The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine.
Haematologica. 2011 Mar;96(3):393-9. doi: 10.3324/haematol.2010.032680. Epub 2010 Dec 6.
9
Topoisomerase IIbeta negatively modulates retinoic acid receptor alpha function: a novel mechanism of retinoic acid resistance.
Mol Cell Biol. 2008 Mar;28(6):2066-77. doi: 10.1128/MCB.01576-07. Epub 2008 Jan 22.
10
Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions.
BMC Mol Biol. 2007 May 20;8:36. doi: 10.1186/1471-2199-8-36.
本文引用的文献
1
Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance.
Int J Cancer. 1999 Mar 1;80(5):744-50. doi: 10.1002/(sici)1097-0215(19990301)80:5<744::aid-ijc19>3.0.co;2-5.
2
Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Cancer Chemother Pharmacol. 1998;41(5):353-60. doi: 10.1007/s002800050751.
3
4
Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein.
Int J Cancer. 1997 May 29;71(5):817-24. doi: 10.1002/(sici)1097-0215(19970529)71:5<817::aid-ijc20>3.0.co;2-3.
5
Mechanism of action of topoisomerase II-targeted antineoplastic drugs.
Adv Pharmacol. 1994;29B:105-26. doi: 10.1016/s1054-3589(08)61134-5.
6
Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
Cancer Res. 1993 Mar 15;53(6):1373-9.
7
Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.
J Cell Physiol. 1993 May;155(2):414-25. doi: 10.1002/jcp.1041550224.
8
A novel mutant topoisomerase II alpha present in VP-16-resistant human melanoma cell lines has a deletion of alanine 429.
Biochemistry. 1994 Sep 20;33(37):11327-32. doi: 10.1021/bi00203a030.
9
10
Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide.
Proc Natl Acad Sci U S A. 1984 Mar;81(5):1361-5. doi: 10.1073/pnas.81.5.1361.
Zotero 插件